Trials / Not Yet Recruiting
Not Yet RecruitingNCT07269769
A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD
A Phase III , Randomized, Double-blind, Placebo-Controlled, Ranibizumab Injection Loading, Multicenter Clinical Trial Comparing the Efficacy and Safety of Sanhuang Jingshiming Pills in Subjects With nAMD
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 450 (estimated)
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the TSL-TCM-SHJSMW-Ⅲ study is to study the efficacy and safety of Sanhuang Jingshiming Pills in subjects with Neovascular Age-Related Macular Degeneration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sanhuang Jingshiming/Pills placebo | Ranibizumab: 1 dose/study eye (Screening/Baseline), then PRN injections |
Timeline
- Start date
- 2026-04-30
- Primary completion
- 2031-12-31
- Completion
- 2031-12-31
- First posted
- 2025-12-08
- Last updated
- 2026-04-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07269769. Inclusion in this directory is not an endorsement.